Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 521586, 12 pages
Review Article

MicroRNA: Important Player in the Pathobiology of Multiple Myeloma

1Experimental Therapeutics, Cancer Science Institute of Singapore, No. 12-02, Centre for Translational Medicine, 14 Medical Drive, Singapore 117599
2Yong Loo Lin School of Medicine, NUHS Tower Block level 11, 1E Kent Ridge Road, Singapore 119228
3Department of Hematology-Oncology, National University Cancer Institute, National University Health System, 1E, Kent Ridge Road, Singapore 119228

Received 26 March 2014; Accepted 19 May 2014; Published 3 June 2014

Academic Editor: Kazuyuki Shimizu

Copyright © 2014 Chonglei Bi and Wee Joo Chng. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Recent studies have revealed a pivotal role played by a class of small, noncoding RNAs, microRNA (miRNA), in multiple myeloma (MM), a plasma cell (PC) malignancy causing significant morbidity and mortality. Deregulated miRNA expression in patient’s PCs and plasma has been associated with tumor progression, molecular subtypes, clinical staging, prognosis, and drug response in MM. A number of important oncogenic and tumor suppressor miRNAs have been discovered to regulate important genes and pathways such as p53 and IL6-JAK-STAT signaling. miRNAs may also form complex regulatory circuitry with genetic and epigenetic machineries, the deregulation of which could lead to malignant transformation and progression. The translational potential of miRNAs in the clinic is being increasingly recognized that they could represent novel biomarkers and therapeutic targets. This review comprehensively summarizes current progress in delineating the roles of miRNAs in MM pathobiology and management.